Similar to IL-1β monoclonal antibodies, canakinumab has been approved for several auto-inflammatory disorders, including classic SJIA (systemic juvenile idiopathic arthritis), gout, and macrophage activation syndrome. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.